The Potential and Hurdles of Targeted Alpha Therapy - Clinical Trials and Beyond

Overview

Journal Front Oncol

Specialty Oncology

Date 2014 Jan 25

PMID 24459634

Citations 55

Authors

Jorgen Elgqvist

Sofia Frost

Jean-Pierre Pouget

Per Albertsson

Affiliations

Soon will be listed here.

Abstract

This article presents a general discussion on what has been achieved so far and on the possible future developments of targeted alpha (α)-particle therapy (TAT). Clinical applications and potential benefits of TAT are addressed as well as the drawbacks, such as the limited availability of relevant radionuclides. Alpha-particles have a particular advantage in targeted therapy because of their high potency and specificity. These features are due to their densely ionizing track structure and short path length. The most important consequence, and the major difference compared with the more widely used β(-)-particle emitters, is that single targeted cancer cells can be killed by self-irradiation with α-particles. Several clinical trials on TAT have been reported, completed, or are on-going: four using (213)Bi, two with (211)At, two with (225)Ac, and one with (212)Pb/(212)Bi. Important and conceptual proof-of-principle of the therapeutic advantages of α-particle therapy has come from clinical studies with (223)Ra-dichloride therapy, showing clear benefits in castration-resistant prostate cancer.

Citing Articles

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy.

Michaeli O, Luz I, Vatarescu M, Manko T, Weizman N, Korotinsky Y Cell Death Dis. 2024; 15(6):426.

PMID: 38890278 PMC: 11189442. DOI: 10.1038/s41419-024-06830-3.

A Technique to Quantify Very Low Activities in Regions of Interest With a Collimatorless Detector.

Caravaca J, Bobba K, Du S, Peter R, Gullberg G, Bidkar A IEEE Trans Med Imaging. 2024; 43(8):2745-2757.

PMID: 38478457 PMC: 11293990. DOI: 10.1109/TMI.2024.3377142.

Targeted Alpha Therapy: All We Need to Know about Ac's Physical Characteristics and Production as a Potential Theranostic Radionuclide.

Jalloul W, Ghizdovat V, Stolniceanu C, Ionescu T, Grierosu I, Pavaleanu I Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139806 PMC: 10747780. DOI: 10.3390/ph16121679.

Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications.

Nelson B, Wilson J, Andersson J, Wuest F Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004486 PMC: 10674391. DOI: 10.3390/ph16111622.

Commercial and business aspects of alpha radioligand therapeutics.

Ostuni E, Taylor M Front Med (Lausanne). 2023; 9:1070497.

PMID: 36816719 PMC: 9932801. DOI: 10.3389/fmed.2022.1070497.

References

Palm S, Elgqvist J, Jacobsson L . Patient-specific alpha-particle dosimetry. Curr Radiopharm. 2011; 4(4):329-35. DOI: 10.2174/1874471011104040329. View

Bodet-Milin C, Ferrer L, Pallardy A, Eugene T, Rauscher A, Faivre-Chauvet A . Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma. Front Oncol. 2013; 3:177. PMC: 3708100. DOI: 10.3389/fonc.2013.00177. View

Andersson H, Cederkrantz E, Back T, Divgi C, Elgqvist J, Himmelman J . Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study. J Nucl Med. 2009; 50(7):1153-60. DOI: 10.2967/jnumed.109.062604. View

Barendsen G, WALTER H . EFFECTS OF DIFFERENT IONIZING RADIATIONS ON HUMAN CELLS IN TISSUE CULTURE. IV. MODIFICATION OF RADIATION DAMAGE. Radiat Res. 1964; 21:314-29. View

Chang C, Sharkey R, Rossi E, Karacay H, McBride W, Hansen H . Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther. 2002; 1(7):553-63. View

Barendsen G, WALTER H, Fowler J, BEWLEY D . Effects of different ionizing radiations on human cells in tissue culture. III. Experiments with cyclotron-accelerated alpha-particles and deuterons. Radiat Res. 1963; 18:106-19. View

Hernandez M, Knox S . Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2004; 59(5):1274-87. DOI: 10.1016/j.ijrobp.2004.02.065. View

Olafsen T, Kenanova V, Wu A . Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc. 2007; 1(4):2048-60. DOI: 10.1038/nprot.2006.322. View

Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S . Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010; 37(7):1335-44. DOI: 10.1007/s00259-010-1385-5. View

10.

Boerman O, van Schaijk F, Oyen W, Corstens F . Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003; 44(3):400-11. View

11.

Sgouros G, Ballangrud A, Jurcic J, McDevitt M, Humm J, Erdi Y . Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999; 40(11):1935-46. View

12.

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

13.

Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H . Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol. 2006; 33(8):1065-72. DOI: 10.1016/j.nucmedbio.2006.07.009. View

14.

Kneifel S, Cordier D, Good S, Ionescu M, Ghaffari A, Hofer S . Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res. 2006; 12(12):3843-50. DOI: 10.1158/1078-0432.CCR-05-2820. View

15.

Bruland O, Nilsson S, Fisher D, Larsen R . High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?. Clin Cancer Res. 2006; 12(20 Pt 2):6250s-6257s. DOI: 10.1158/1078-0432.CCR-06-0841. View

16.

Kassis A, Harris C, Adelstein S, Ruth T, Lambrecht R, Wolf A . The in vitro radiobiology of astatine-211 decay. Radiat Res. 1986; 105(1):27-36. View

17.

Williams J, Edwards J, Dillehay L . Quantitative comparison of radiolabeled antibody therapy and external beam radiotherapy in the treatment of human glioma xenografts. Int J Radiat Oncol Biol Phys. 1992; 24(1):111-7. DOI: 10.1016/0360-3016(92)91029-m. View

18.

Palm S, Humm J, Rundqvist R, Jacobsson L . Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys. 2004; 31(2):218-25. DOI: 10.1118/1.1640951. View

19.

Pool S, Krenning E, Koning G, van Eijck C, Teunissen J, Kam B . Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010; 40(3):209-18. DOI: 10.1053/j.semnuclmed.2009.12.001. View

20.

Park S, Shenoi J, Pagel J, Hamlin D, Wilbur D, Orgun N . Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010; 116(20):4231-9. PMC: 2993626. DOI: 10.1182/blood-2010-05-282327. View